Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

Zen­tal­is isn’t the on­ly biotech to de­fy ex­pec­ta­tions as fi­nan­cial mar­kets across the globe roil from the shock of the coro­n­avirus pan­dem­ic. Keros Ther­a­peu­tics has man­aged to ex­e­cute an IPO, hit­ting the top end of its pric­ing range and sell­ing more shares than orig­i­nal­ly en­vi­sioned, as it shep­herds its lead drug in­to mid-stage de­vel­op­ment.

The Lex­ing­ton, Mass­a­chu­setts-based com­pa­ny’s pipeline of drugs tar­get a fam­i­ly of pro­teins called trans­form­ing growth fac­tor-be­ta (TGF-β), sig­nal­ing path­ways that reg­u­late blood cell and platelet pro­duc­tion, and growth, re­pair, and main­te­nance of mus­cle and bone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER